EUVIMEDEUVIMED entdecken
Open Access

High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients

Y Lisa Hwa iD, Dragan Jevremovic, Karen Pak, Prashant Kapoor, Alissa Visram, Morie A Gertz iD, David D Dingli, Francis K Buadi, Ronald S Go iD, Rahma Warsame, Nelson Leung iD, Wilson I Gonsalves und 10 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Y Lisa Hwa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Iron Deficiencies, Anemia, Iron-Deficiency. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iron deficiency (ID) is often overlooked in patients with haematological malignancies due to other potential aetiologies. Daratumumab, an anti‐cluster of differentiation 38 (anti‐CD38) monoclonal antibody, is commonly used for treating multiple myeloma (MM) in the upfront and relapsed/refractory settings. Although anaemia is a common haematological toxicity associated with daratumumab, the contribution of ID in MM patients has not been systematically investigated. We conducted a retrospective case–control study to evaluate the prevalence of ID in newly diagnosed MM (NDMM) patients. Cases were patients receiving daratumumab, ixazomib, lenalidomide and dexamethasone (Dara‐IRD, n = 55). We compared this group with an age‐ and sex‐matched cohort of patients with NDMM who received bortezomib, lenalidomide and dexamethasone (VRD, n = 20) as induction therapy. At 1‐year, nearly 50% of Dara‐IRD‐treated patients met the criteria for ID (ferritin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, MonoclonalIron DeficienciesAnemia, Iron-DeficiencyHumansFemaleRetrospective StudiesAgedMaleCase-Control StudiesPrevalenceMiddle AgedDexamethasoneAged, 80 and overLenalidomideAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

daratumumabiron deficiencymultiple myeloma

Substanzen

daratumumabAntibodies, MonoclonalDexamethasoneLenalidomide

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

ORCID-Profile: Y Lisa Hwa, Morie A Gertz, Ronald S Go, Nelson Leung, Joselle M Cook, Moritz Binder, S Vincent Rajkumar, Eli Muchtar

Zitieren

APA

Hwa, Y. L., Jevremovic, D., Pak, K., Kapoor, P., Visram, A., Gertz, M. A., Dingli, D. D., Buadi, F. K., Go, R. S., Warsame, R., Leung, N., Gonsalves, W. I., Hobbs, M. A., Fonder, A. L., Cook, J. M., Binder, M., Hayman, S. R., Kourelis, T., Rajkumar, S. V., …, & Muchtar, E. (2026). High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients. British Journal of Haematology. https://doi.org/10.1111/bjh.70697

Vancouver

Hwa YL, Jevremovic D, Pak K, Kapoor P, Visram A, Gertz MA, et al. High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients. British Journal of Haematology. 2026. doi:10.1111/bjh.70697

BibTeX
@article{Hwa2026,
  author = {Hwa, Y Lisa and Jevremovic, Dragan and Pak, Karen and Kapoor, Prashant and Visram, Alissa and Gertz, Morie A and Dingli, David D and Buadi, Francis K and Go, Ronald S and Warsame, Rahma and Leung, Nelson and Gonsalves, Wilson I and Hobbs, Miriam A and Fonder, Amie L and Cook, Joselle M and Binder, Moritz and Hayman, Suzanne R and Kourelis, Taxiarchis and Rajkumar, S Vincent and Dispenzieri, Angela and Kumar, Shaji K and Muchtar, Eli},
  title = {High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70697}
}
Kostenlos starten →